10.1002/9780470718896.ch6
Wooley DW, Shaw E: A biological and pharmacological suggestion about certain mental disorders. Proc NatI Acad Sci USA 1954
10.1001/archpsyc.1972.01750260021004
10.1001/archpsyc.1988.01800330013001
10.1111/j.1600-0447.1990.tb05280.x
10.1097/00004714-199302000-00004
Dahlstr A, 1964, Acta Physiol Scand, 62, 1
10.1016/0306-4522(81)90146-9
10.1016/0006-8993(76)91023-4
10.1016/0006-8993(87)91588-5
10.1016/0006-8993(76)90005-6
10.1016/0006-8993(78)91077-6
10.1016/0306-4522(77)90120-8
10.1016/0028-3908(86)90207-8
Hoyer D, 1994, Pharmacol Rev, 46, 157
10.1016/0028-3908(94)90058-2
10.1016/0006-8993(86)90902-9
10.1111/j.1476-5381.1957.tb00142.x
10.1016/0006-8993(86)90903-0
10.1111/j.1471-4159.1993.tb03208.x
Shen Y, 1993, Biol Chem, 268, 18200, 10.1016/S0021-9258(17)46830-X
Roth BL, 1994, J Pharmacol Exp Ther, 268, 1403
Monsma FJ Jr, 1993, Mol Pharmacol, 43, 320
10.1111/j.1749-6632.1962.tb50103.x
10.1177/002076406300900401
10.1097/00005053-196808000-00008
10.3928/0048-5713-19940301-09
10.1016/0024-3205(84)90436-3
Stahl SM, 1987, Handbook of Schizophrenia, vol 2: Neurochemistry and Neuropharmacology of Schizophrenia, 257
10.1016/S0140-6736(66)92028-9
10.1016/0028-3908(69)90046-X
10.1111/j.1600-0447.1977.tb00229.x
10.1016/0022-3999(71)90051-1
10.1001/archpsyc.1975.01760260127011
10.1001/archpsyc.1974.01760130034005
10.1016/0165-1781(83)90003-3
Losonczy MF, Song IS, Mohs RC, etal: Correlates of lateral ventricular size in chronic schizophrenia, II: biological measures. Am .1 Psychiatry 1986; 143:1113-1118
10.1016/0165-1781(85)90001-0
10.1111/j.1749-6632.1986.tb27898.x
10.1001/archpsyc.1988.01800310013001
10.1111/j.1749-6632.1988.tb42115.x
10.1001/archpsyc.1993.01820200009001
10.1111/j.1600-0447.1979.tb00261.x
Farley IJ, 1980, Enna SJ, 427
10.1001/archpsyc.1993.01820220066007
10.1046/j.1471-4159.1995.64031197.x
Peroutka SJ, 1979, Mol Pharmacol, 16, 687
10.1001/archpsyc.1979.01780090013001
10.1001/archpsyc.1981.01780280046004
Leysen JE, 1990, Neuropsychopharmacology, 3, 361
Choudhary MS., 1992, Mol Pharmacol, 42, 627
10.1016/0006-3223(86)90332-X
Reynolds CP, 1983, J Neural Transm, 18, 273
10.1016/0024-3205(83)90162-5
10.1111/j.1471-4159.1986.tb12944.x
10.3109/10799898709054987
Leysen JE, Van Nueten JM, et al: [3H]Ketanserin (R 41 468), a selective H-ligand for serotonin-2 receptor binding sites: binding properties, brain distribution and functional role. Mo! Pharmacol 1982
10.1016/0014-2999(87)90544-9
10.1001/archpsyc.1990.01810230054009
10.1016/0006-8993(93)91015-K
10.1001/archpsyc.1986.01800100048007
10.1016/S0140-6736(83)92590-4
10.1016/0006-8993(88)91621-6
10.1016/0006-8993(86)91415-0
10.1016/0006-8993(94)90932-6
10.1016/0006-8993(90)90274-F
10.1016/S0140-6736(83)91310-7
10.1016/0024-3205(91)90556-Q
10.1016/0006-8993(93)90191-O
10.3109/10799898809048978
10.1016/0006-3223(89)90217-5
10.1016/0006-3223(91)90184-N
Conn PJ, 1987, J Pharmacol Exp Ther, 242, 552
10.1016/0197-0186(91)90117-V
10.1016/0165-1781(91)90013-F
10.1016/0006-3223(91)90233-C
10.1001/archpsyc.1993.01820200034004
10.1016/0165-1781(92)90136-Q
10.1016/0006-3223(93)90241-5
10.1001/archpsyc.1993.01820200046005
Wurtman RJ, 1981, Pharmacol Rev, 32, 315
10.1001/archneurpsyc.1958.02340070140021
10.1126/science.133.3446.104
10.1016/0028-3908(70)90011-0
Cil J, Wyatt R: Clinical effects of tryptophan in chronic schizophrenic patients. Bio! Psychiatry 1976
Chouinard G, et a!: A controlled study of tryptophan-benserazide in schizophreni Communications in Psychopharmacology 1978
Morand C, 1983, Biol Psychiatry, 18, 575
10.1126/science.177.4054.1124
Bige L, Clinical effects of L-5-hydroxytryptophan administration in chronic schizophrenic patients. Bio! Psychiatry 1979
10.1016/0006-3223(87)90134-X
Casacchia M, 1975, Biol Psychiatry, 10, 109
DeLisi L, 1982, Biol Psychiatry, 11, 471
10.1016/0006-3223(85)90068-X
10.1016/0006-3223(85)90008-3
Soper HV, 1990, J Clin Psychopharmacol, 10, 168, 10.1097/00004714-199006000-00003
Baldessarini RJ, Frankenburg FR: Clozapine: a novel antipsychotic agent. N EngI J Med 1991
10.1016/0920-9964(91)90030-U
10.1192/S0007125000292544
Seeman P, 1992, Neuropsychopharmacology, 7, 261
10.1016/0014-2999(90)94100-C
Deutch AY, Regionally specific effects of atypical antipsychotic drugs on striata! fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mo! Cell Neurosci 1992
10.1016/0361-9230(86)90181-4
Rasmussen K, Aghajanian CK: Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity. Neuropsychopharmaco! 1988
Me H, 1989, Psychopharmacology, 99, S18, 10.1007/BF00442554
Meltzer H, D-2, and serotomn 2 pki values. J Pharmaco! Exp Ther 1989
Meco C, 1989, Current Therapy Research, 46, 876
10.1111/j.1600-0447.1992.tb01473.x
10.1111/j.1600-0447.1993.tb03480.x
10.1192/S0007125000295950
Bersani C, Crispini A, Marii S, eta!: 5-HT2 antagonist ritanserin in neuroleptic induced parkinsonism: a double blind comparison with orphenadrine and placebo. Clin Neuropharmaco! 1990; 13:500-506
Miller CH, et a!: Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmaco! Bull 1990
Bleekers E, 1990, Collegium Internationale Neuro-psychopharmacologicum (CINP)
Sorensen SM, eta!: Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmaco! Exp Ther 1993
Rossum V, The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Arch mt Pharmacodyn Ther 1966
Car A, 1963, Acta Pharmacol Toxicol, 20, 140, 10.1111/j.1600-0773.1963.tb01730.x
10.1016/S0166-2236(84)80062-4
Hornykiewicz 0, 1986, The Neurobiology of Dopamine Systems
10.1001/archpsyc.1973.04200020023003
10.1001/archpsyc.1987.01800190080012
10.1016/0306-4522(91)90196-U
10.1016/0014-2999(68)90021-6
10.1016/0028-3908(71)90005-0
10.1016/0006-8993(74)90433-8
10.1016/0006-8993(75)90060-8
10.1016/0006-8993(76)91024-6
10.1016/0006-8993(73)90429-0
10.1016/0006-8993(75)90233-4
10.1016/0031-9384(72)90026-1
10.1016/0028-3908(79)90122-9
10.1016/0014-2999(74)90019-3
Green TK, Harvey JA: Enhancement of amphetamine action after interruption of ascending serotonergic pathways. J Pharmaco! Exp Ther 1974
10.1016/0006-8993(76)90904-5
10.1111/j.1476-5381.1974.tb09714.x
Hollister A, 1976, J Pharmacol Exp Ther, 198, 12
10.1016/0028-3908(75)90054-4
Neuburg J, 1974, Biol Psychiatry, 8, 139
Crabowska ML, 1973, Polish Journal of Pharmacology and Pharmacy, 25, 29
10.1016/0006-8993(75)90295-4
10.1111/j.2042-7158.1976.tb02783.x
10.1016/0014-2999(81)90556-2
10.1016/0014-2999(69)90202-7
10.1016/0006-8993(69)90122-X
Ernst AM, 1972, Archives Internationales de Pharmacodynamie, 199, 219
10.1016/0014-2999(72)90230-0
10.1016/0306-4522(80)90048-2
10.1111/j.2042-7158.1976.tb04140.x
10.1016/0006-8993(78)91110-1
10.1111/j.2042-7158.1980.tb12889.x
10.1016/0014-2999(79)90492-8
10.1111/j.2042-7158.1978.tb13188.x
10.1016/0014-2999(81)90038-8
Blackburn TP, 1979, Br J Pharmacol, 67, 431
10.1016/0006-8993(75)90060-8
10.1016/0024-3205(79)90396-5
10.1016/0006-8993(87)90683-4
Fog R, 1972, Acta Neurol Scand, 48, 3
10.1016/0006-8993(72)90208-9
10.1016/0028-3908(75)90114-8
Carter CJ, 1977, Br J Pharmacol, 60, 267P
10.1016/0014-2999(79)90110-9
10.1016/0024-3205(90)90365-X
10.1111/j.2042-7158.1983.tb02880.x
10.1016/0014-2999(91)90235-I
Coldstein JM, 1989, J Pharmacol Exp Ther, 249, 673
10.1016/0014-2999(94)00698-7
10.1016/0014-2999(93)90555-V
Pehek EA, 1993, Society for Neuroscience Abstracts, 19, 302
10.1111/j.1471-4159.1990.tb01230.x
10.1097/00004714-199502001-00003
10.1111/j.1748-1716.1989.tb08640.x
Svensson TH, 1993, Schizophr Res, 11, 115P
10.1111/j.1748-1716.1989.tb08694.x
Crenhoffj CS, 1990, Pharmacol Toxicol, 29
10.1016/0166-4328(86)90032-X
10.1016/0024-3205(90)90484-9
10.1046/j.1471-4159.1994.62041382.x
10.1016/0165-0173(81)90004-7
10.1111/j.1471-4159.1988.tb02919.x
10.1016/0014-2999(93)90859-G
10.1016/0006-8993(95)00865-N
10.1097/00004850-199311002-00004
Laruelle M, Proc NatI Acad Sd USA 1996; 93:9235-9240
10.1016/0006-8993(93)90402-9
10.1016/0014-2999(94)90502-9
10.1001/archpsyc.1991.01810350036005
Selemon LD, 1993, Society for Neuroscience Abstracts, 19, 200
10.1016/0006-3223(93)90065-L
10.1001/archpsyc.1995.03950160008002
Arnold SE, Abnormal expression of two microtubule associated proteins (MAP2 and MAP5) in specific subfields of the hippocampal formation in schizophrenia. Proc NatI Acad Sci USA 1991
10.1016/0893-133X(94)00081-A
10.1016/0163-1047(91)80140-A
10.1016/0024-3205(86)90060-3
10.1016/0361-9230(89)90198-6
10.1016/0165-0173(93)90008-N
Laruelle M, Abi-Dargham A, van Dyck CH, etal: SPECT imaging of striatal dopamine release after amphetamine challenge. J NucI Med 1995; 36:1182-1190
